PMID- 37846397
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 15
DP  - 2023
TI  - Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage 
      small-cell lung cancer: a network meta-analysis of randomized controlled trial.
PG  - 17588359231206147
LID - 10.1177/17588359231206147 [doi]
LID - 17588359231206147
AB  - BACKGROUND: Recently, several new first-line immune checkpoint inhibitors (ICIs) 
      plus chemotherapy have been approved for patients with extensive-stage small-cell 
      lung cancer (ES-SCLC). However, direct comparisons between first-line treatments 
      are lacking. Therefore, we indirectly compared the efficacy and safety of 
      specific treatment strategies to inform physicians' and patients' clinical 
      decisions. METHODS: The Pubmed, Cochrane, Embase, and Web of Science databases 
      were searched from 1 January 2000 to 27 November 2022, for randomized clinical 
      trials (RCTs) assessing first-line immuno-chemotherapies for ES-SCLC. A 
      fixed-effect multivariable meta-regression model was established for frequentist 
      network meta-analysis and hazard ratios (HRs) with 95% confidence intervals (95% 
      CI) were computed to compare the effects of immuno-chemotherapies on patient 
      overall survival (OS) and progression-free survival (PFS), while risk ratios with 
      95% CI were used for treatment- and immune-related adverse events (AEs). The p 
      score values were then used to rank treatments based on their odds of being the 
      best treatment option. The research protocol was registered with the PROSPERO 
      (CRD42022383254). RESULTS: Seven studies involving 3822 patients were eligible 
      for analysis. Serplulimab plus chemotherapy had better OS outcomes compared to 
      chemotherapy (HR = 0.63; 95% CI: 0.49-0.82) and ipilimumab plus chemotherapy (HR 
      = 0.67; 95% CI: 0.50-0.90). It additionally exhibited better PFS outcomes 
      compared to chemotherapy (HR = 0.48; 95% CI: 0.39-0.60), adebrelimab (HR = 0.72; 
      95% CI: 0.53-0.97), atezolizumab (HR = 0.62; 0.46-0.85), durvalumab (HR = 0.60; 
      95% CI: 0.45-0.80), durvalumab and tremelimumab (HR = 0.57; 95% CI: 0.43-0.76), 
      ipilimumab (HR = 0.57; 95% CI: 0.44-0.73), and pembrolizumab (HR = 0.64; 95% CI: 
      0.48-0.86) plus chemotherapy. Serplulimab plus chemotherapy was linked to the 
      greatest odds of effectively reducing the odds of death (p score = 0.87) and 
      progression (p score = 0.99) while exhibiting a good safety profile. CONCLUSION: 
      Serplulimab plus chemotherapy exhibited the best survival outcomes with 
      manageable AEs. Thus, serplulimab plus chemotherapy may represent the optimal 
      best first-line treatment option for ES-SCLC patients.
CI  - (c) The Author(s), 2023.
FAU - Zhu, Youwen
AU  - Zhu Y
AUID- ORCID: 0000-0001-8692-3591
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
FAU - Liu, Kun
AU  - Liu K
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
FAU - Zhu, Hong
AU  - Zhu H
AUID- ORCID: 0000-0002-3659-8070
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
FAU - Cao, Hui
AU  - Cao H
AD  - Department of Oncology, Chenzhou First People's Hospital, Chenzhou, Hunan 423000, 
      China.
FAU - Zhou, Yangying
AU  - Zhou Y
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, Hunan 410008, China.
LA  - eng
PT  - Journal Article
DEP - 20231014
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC10576922
OTO - NOTNLM
OT  - clinical trials
OT  - extensive-stage small-cell lung cancer
OT  - immuno-chemotherapy
OT  - network meta-analysis
OT  - survival
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/10/17 06:42
MHDA- 2023/10/17 06:43
PMCR- 2023/10/14
CRDT- 2023/10/17 03:52
PHST- 2023/03/07 00:00 [received]
PHST- 2023/09/18 00:00 [accepted]
PHST- 2023/10/17 06:43 [medline]
PHST- 2023/10/17 06:42 [pubmed]
PHST- 2023/10/17 03:52 [entrez]
PHST- 2023/10/14 00:00 [pmc-release]
AID - 10.1177_17588359231206147 [pii]
AID - 10.1177/17588359231206147 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2023 Oct 14;15:17588359231206147. doi: 
      10.1177/17588359231206147. eCollection 2023.